Trial Profile

A Phase II Study of Gemcitabine and Nab-Paclitaxel in Combination With GDC-0449 (Hedgehog Inhibitor) in Patients With Previously Untreated Metastatic Adenocarcinoma of the Pancreas

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 04 Mar 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Vismodegib (Primary) ; Gemcitabine; Paclitaxel
Indications Adenocarcinoma; Pancreatic cancer; Pancreatic ductal carcinoma
Focus Adverse reactions; Therapeutic Use

Most Recent Events

20 Dec 2019 Results published in the British Journal of Cancer
02 Apr 2019 Status changed from active, no longer recruiting to completed.
27 May 2015 Planned End Date changed from 1 Dec 2013 to 1 Oct 2015 as reported by ClinicalTrials.gov

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com